These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 18833117)

  • 1. [Atomoxetine and piracetam in the treatment of attention deficit hyperactivity disorder in children].
    Zavadenko NN; Suvorinova NIu
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(7):43-7. PubMed ID: 18833117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effectiveness of strattera in children and adolescents with attention deficit hyperactivity disorder].
    Vakula IN; Vasianina IuSh; Gorbunova ZKh; Nikiforova EIu; Ponomarenko EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(8):42-4. PubMed ID: 19738568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled clinical trial on once-daily atomoxetine in Taiwanese children and adolescents with attention-deficit/hyperactivity disorder.
    Gau SS; Huang YS; Soong WT; Chou MC; Chou WJ; Shang CY; Tseng WL; Allen AJ; Lee P
    J Child Adolesc Psychopharmacol; 2007 Aug; 17(4):447-60. PubMed ID: 17822340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Atomoxetine (strattera) in the treatment of attention deficit hyperactivity syndrome].
    Ershova A
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(10):87-91. PubMed ID: 19097312
    [No Abstract]   [Full Text] [Related]  

  • 6. Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study.
    Troost PW; Steenhuis MP; Tuynman-Qua HG; Kalverdijk LJ; Buitelaar JK; Minderaa RB; Hoekstra PJ
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):611-9. PubMed ID: 17069549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.
    Harfterkamp M; Buitelaar JK; Minderaa RB; van de Loo-Neus G; van der Gaag RJ; Hoekstra PJ
    J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):194-9. PubMed ID: 23578015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder.
    Chang K; Nayar D; Howe M; Rana M
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):547-51. PubMed ID: 19877979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Electroencephalographic study of children with attention deficit hyperactivity disorder before and after treatment with strattera].
    Nikishina IS; Chutko LS; Surushina SIu; Iakovenko EA; Kropotov IuD
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(12):60-2. PubMed ID: 19253469
    [No Abstract]   [Full Text] [Related]  

  • 10. Improving visual memory, attention, and school function with atomoxetine in boys with attention-deficit/hyperactivity disorder.
    Shang CY; Gau SS
    J Child Adolesc Psychopharmacol; 2012 Oct; 22(5):353-63. PubMed ID: 23083022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of atomoxetine and quality of life in children with attention-deficit/hyperactivity disorder as perceived by patients, parents, and physicians in an open-label study.
    Wehmeier PM; Dittmann RW; Schacht A; Minarzyk A; Lehmann M; Sevecke K; Lehmkuhl G
    J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):813-30. PubMed ID: 18315453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination use of atomoxetine hydrochloride and olanzapine in the treatment of attention-deficit/hyperactivity disorder with comorbid disruptive behavior disorder in children and adolescents 10-18 years of age.
    Holzer B; Lopes V; Lehman R
    J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):415-8. PubMed ID: 23952189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders.
    Posey DJ; Wiegand RE; Wilkerson J; Maynard M; Stigler KA; McDougle CJ
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):599-610. PubMed ID: 17069548
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement of executive functions in boys with attention deficit hyperactivity disorder: an open-label follow-up study with once-daily atomoxetine.
    Gau SS; Shang CY
    Int J Neuropsychopharmacol; 2010 Mar; 13(2):243-56. PubMed ID: 19849892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A meta-analysis of the consistency of atomoxetine treatment effects in pediatric patients with attention-deficit/hyperactivity disorder from 15 clinical trials across four geographic regions.
    Tanaka Y; Rohde LA; Jin L; Feldman PD; Upadhyaya HP
    J Child Adolesc Psychopharmacol; 2013 May; 23(4):262-70. PubMed ID: 23683141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suboptimal dosing of Strattera (atomoxetine) for ADHD patients.
    Clemow DB
    Postgrad Med; 2014 Sep; 126(5):196-8. PubMed ID: 25420287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents.
    Scott NG; Ripperger-Suhler J; Rajab MH; Kjar D
    J Child Adolesc Psychopharmacol; 2010 Jun; 20(3):197-203. PubMed ID: 20578932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Safety of Atomoxetine for the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Comprehensive Review of Over a Decade of Research.
    Reed VA; Buitelaar JK; Anand E; Day KA; Treuer T; Upadhyaya HP; Coghill DR; Kryzhanovskaya LA; Savill NC
    CNS Drugs; 2016 Jul; 30(7):603-28. PubMed ID: 27290715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of atomoxetine on executive functioning and lexical decision in attention-deficit/hyperactivity disorder and reading disorder.
    de Jong CG; Van De Voorde S; Roeyers H; Raymaekers R; Allen AJ; Knijff S; Verhelst H; Temmink AH; Smit LM; Rodriques-Pereira R; Vandenberghe D; van Welsen I; ter Schuren L; Al-Hakim M; Amin A; Vlasveld L; Oosterlaan J; Sergeant JA
    J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):699-707. PubMed ID: 20035588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atomoxetine versus placebo in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: a double-blind, randomized, multicenter trial in Germany.
    Dittmann RW; Schacht A; Helsberg K; Schneider-Fresenius C; Lehmann M; Lehmkuhl G; Wehmeier PM
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):97-110. PubMed ID: 21488751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.